Exelixis, StemSynergy in CSNK1A activator deal

Exelixis Inc. (NASDAQ:EXEL) and StemSynergy Therapeutics Inc. (Miami, Fla.) partnered to discover and develop compounds targeting casein kinase 1 alpha (CSNK1A; CKI-alpha) to treat cancer.

The partners will conduct preclinical and clinical studies of compounds from StemSynergy's CSNK1A activator program. Exelixis will commercialize resulting products...